Latest News-Ascletis Pharma Inc. Mediaroom_Page

Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist

-Ultra-long-acting subcutaneous (SQ) injection formulation of small molecule ASC30 demonstrated a 3...

2025-03-31 19:00 3219

Ascletis Pharma to Host Obesity Portfolio Webinar on April 2, 2025

HONG KONG, March 20, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces it...

2025-03-20 19:00 4424

Ascletis Announces Positive Topline Results of Phase Ib Studies of ASC47 Monotherapy in Australia and U.S. FDA Clearance of IND Application for ASC47 in Combination with Semaglutide

* ASC47, an adipose-targeted muscle-preserving weight loss drug candidate for the treatment of ob...

2025-03-12 07:30 3399

Ascletis Announces Positive Interim Results from First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30

- ASC30 oral once-daily tablet demonstrated a 6.3% mean body weight reduction from baseline after ...

2025-02-19 20:00 3731

Ascletis Announces Positive Results from U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Provides Program Update

* ASC30 oral tablet demonstrated dose-proportional pharmacokinetic (PK) properties and a long hal...

2025-01-21 19:00 5575

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model

* In a head-to-head diet-induced obese (DIO) mouse study, ASC47 low dose combination 1 (ASC47, 3 ...

2024-12-18 21:43 4783

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

-Phase III trial enrolled a total of 480 patients with moderate to severe acne -Topline results expe...

2024-11-12 19:30 3509

Ascletis Announces Promising Results from a Phase I Study in Australia for First-in-Class Muscle-Preserving Weight Loss Drug Candidate ASC47 for the Treatment of Obesity

* Data from a Phase I single ascending dose (SAD) study in Australia in subjects with elevated lo...

2024-11-07 19:30 4235

Ascletis Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and Once-Daily Oral Tablet for the Treatment of Obesity

- ASC30 is the first and only small molecule GLP-1 receptor (GLP-1R) agonist that can be dosed once...

2024-09-17 18:25 4316

Gannex Announces Poster Presentation of Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy-Confirmed MASH at EASL CONGRESS 2024

--Up to 68.2% mean relative reduction in liver fat content from baseline among biopsy-confirmed met...

2024-06-11 08:10 3039

Ascletis Announces Strategic Decisions on FXR agonist ASC42

HANGZHOU, China and SHAOXING, China, April 3, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672,...

2024-04-03 17:10 3270

Ascletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting

HANGZHOU and SHAOXING, China, March 10, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Asc...

2024-03-11 08:10 2820

Ascletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne

HANGZHOU and SHAOXING, China, Jan. 24, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascl...

2024-01-24 16:50 3927

Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Denifanstat achieved statistically significant results on primary and multiple secondary endpoints ...

2024-01-23 12:17 3904

Gannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic Steatohepatitis

--Up to 68.2% mean relative reduction in liver fat content from baseline in biopsy-confirmed non-al...

2024-01-02 20:06 4388

Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne

--The Phase III clinical trial of ASC40 for moderate to severe acne vulgaris will enroll 480 subjec...

2023-12-05 16:50 3907

Ascletis Announces Poster Presentations at AASLD Annual Meeting 2023 Including a Late-Breaking Abstract of Interim Results from Phase IIb Expansion Cohort of ASC22 for Functional Cure of CHB

HANGZHOU and SHAOXING, China, Nov. 13, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascl...

2023-11-13 08:10 3733

Dr. Jinzi J. Wu Presents at the 10th International Workshop on HBV Cure 2023

HANGZHOU and SHAOXING, China, Nov. 9, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascle...

2023-11-09 08:10 6210

Gannex Published Phase I Data of ASC42, a Novel Farnesoid X Receptor Agonist on the Journal Drugs in R&D

SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- Gannex Pharma Co., Ltd. ("Gannex"), a wholly-owned company o...

2023-11-06 12:20 3076

Ascletis Announces Poster Presentation of Phase II Study Topline Results of FASN Inhibitor ASC40 for Treatment of Acne at EADV Congress 2023

HANGZHOU and SHAOXING, China, Oct. 11, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascl...

2023-10-11 08:10 3779